Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Invivyd, Inc./ 3

Initial Beneficial Ownership · 3

Invivyd, Inc.

IVVDNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Sep 2, 2026Accepted Sep 2, 2026, 4:40 PM EDTFiling CIK 1832038Accession 0001193125-26-380335
View company →Permanent SEC source ↗
Share

Structured filing — 3

ownership.xml

Open full document ↗

Filing details

Report period
2026-08-30
Issuer
Invivyd, Inc.
Issuer CIK
0001832038
Trading symbol
IVVD
No securities owned
Checked

Reporting owner 1

Name
Sheffield Ian
Reporting owner CIK
0001594410
Relationship
Director
Address
C/O INVIVYD, INC., 205 CHURCH STREET, NEW HAVEN, CT, 06510

Remarks

Exhibit 24.1: Power of Attorney

Signature 1

Signed
/s/ Jill Andersen attorney-in-fact for Ian Sheffield
Date
2026-09-02

Filed exhibits

Company context

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Current securities

IVVDNASDAQ · EQUITY · Current

Recent company filings

  1. Other EventsSep 29, 2026
  2. 4 filingSep 2, 2026
  3. 4 filingSep 1, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsSep 1, 2026
  5. 4 filingAug 18, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.